Growth in the biomanufacturing industry is growing at 7% according to a recent podcast with Andrew Badrot, Founder and CEO of CMS Pharma and former Vice President of Strategy at Lonza. Driving this growth in biomanufacturing are things like success in late stage clinical trials, increased production and success with the and new regulations geared at biosimilars. What speaker Badrot also points at is the over-proportional growth that will follow in the manufacturing industry. He predicts that it will grow at more than 9%. However, what traditional companies will see is more competition from emerging markets and more companies due to fewer barriers to entries as a result of single use systems.Listen to the full podcast here.
If you're interested in finding out more about the current landscape of biomanufacturing, BioProcess International will take place this September and will continue it's look at product and process development and biomanufacturing scientists and executives to share technical, scientific and strategic solutions across all phases of bioprocess development. For more information on this event, download the agenda. If you'd like to join us September 16-19 in Boston, as a reader of this blog, when you register to join us and mention code BLOG13JP, you'll save 20% off the standard rate.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment